FY2024 Earnings Estimate for uniQure Issued By William Blair

uniQure (NASDAQ:QURE) – William Blair raised their FY2024 EPS estimates for uniQure in a report issued on Wednesday, November 6th. William Blair analyst S. Corwin now anticipates that the biotechnology company will post earnings per share of ($4.14) for the year, up from their prior forecast of ($4.48). The consensus estimate for uniQure’s current full-year earnings is ($4.10) per share. William Blair also issued estimates for uniQure’s Q4 2024 earnings at ($0.73) EPS, Q1 2025 earnings at ($0.73) EPS, Q2 2025 earnings at ($0.73) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.68) EPS and FY2025 earnings at ($2.82) EPS.

QURE has been the subject of a number of other research reports. Royal Bank of Canada dropped their target price on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and issued a $28.00 price objective on shares of uniQure in a research report on Wednesday. Raymond James reissued an “outperform” rating and issued a $20.00 target price on shares of uniQure in a research note on Thursday, October 10th. The Goldman Sachs Group decreased their price target on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a research report on Wednesday. Finally, StockNews.com raised uniQure to a “sell” rating in a research report on Thursday, October 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, uniQure has a consensus rating of “Hold” and an average price target of $17.00.

uniQure Stock Performance

Shares of NASDAQ:QURE opened at $7.79 on Friday. The business has a 50-day moving average of $5.77 and a two-hundred day moving average of $5.83. The firm has a market capitalization of $379.71 million, a PE ratio of -1.57 and a beta of 0.90. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 7.36. uniQure has a 12 month low of $3.73 and a 12 month high of $11.35.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its stake in uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after buying an additional 3,663 shares during the period. Atria Investments Inc acquired a new stake in shares of uniQure during the third quarter valued at about $53,000. Vanguard Personalized Indexing Management LLC increased its position in shares of uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,306 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of uniQure in the third quarter worth about $69,000. Finally, Total Clarity Wealth Management Inc. acquired a new position in shares of uniQure in the second quarter worth about $74,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.